Abstract
Background: The prevalence of bone metastases in advanced breast cancer is high (>70%). QL1206 is a biosimilar for denosumab (Xgeva®, Amgen Inc.) and has demonstrated equivalence to the reference product in previous Ph I bioequivalence trial and Ph III trial. Here we present the results of these analyses in breast cancer subgroup.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
